News & Events

ZS Pharma Presents New Data from ZS003 a Two Week Phase 3 Trial Demonstrating that ZS-9 Prevented Recurrence of Hyperkalemia in Heart Failure Patients on RAASi

Data Featured as Oral Presentation During a Late-Breaking Clinical Trial Session at the Heart Failure Society of America (HFSA) 18th Annual Scientific Meeting  Coppell, Texas – September 15, 2014 - ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced results of a secondary analysis of ZS003, a two week pivotal Phase 3 trial of ZS-9 (sodium zirconium cyclosilicate), its investigational treatment for hyperkalemia. Hyperkalemia is a...

read more

RiverVest invests in Tryton’s $20 million funding round

By:  Brian Feldt, St. Louis Business Journal September 8, 2014 Tryton Medical, a company developing stents to treat coronary bifurcation lesions, has raised $20 million in equity from a group of investors that includes St. Louis-based RiverVest Venture Partners and the 3×5 Special Opportunity Fund. Both RiverVest and the 3X5 fund, which is co-managed by RiverVest, have participated in funding rounds for Tryton before, most recently in a $24 million equity financing round for the Durham, North Carolina-based company in early 2013.  ...

read more

RiverVest Venture Partners’ Otonomy Completes $100 Million Initial Public Offering

ST. LOUIS and SAN DIEGO (Aug. 13, 2014) – Otonomy, Inc., a RiverVest Fund II portfolio company that develops drug therapies for the inner and middle ear, announced today its $100 million initial public offering. The San Diego-based biopharma company priced 6.25 million shares of common stock at a price of $16.00 per share, which starts trading today on the NASDAQ under the symbol OTIC. Otonomy also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock which could increase the gross offering...

read more

Ear biotech Otonomy sets terms for $80 million IPO

Source:  IPO investment firm Renaissance Capital Otonomy, a late-stage biotech developing sustained-exposure treatments for ear diseases, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $80 million by offering 5.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Otonomy would command a fully diluted market value of $315 million. Otonomy’s lead candidate treats middle ear effusion developed during tympanostomy tube placement surgery. The company plans to submit...

read more

Tryton Medical Enrolls First Patient in the EXTENDED Access Registry A Single Arm Study Designed to Support FDA Submission for US Approval

Durham, N.C. – July 28, 2014 – Tryton Medical, Inc., the leading developer of stents to treat bifurcation lesions, announced that the first patient has been enrolled in the EXTENDED Access Registry (Tryton IDE XA registry), a single arm study of its Tryton Side Branch Stent. The Tryton IDE XA registry is designed to support FDA submission for US approval and is expected to enroll 133 patients from Europe and the United States. Indulis Kumsars, M.D. of P. Stradins University Hospital, Latvian Centre of Cardiology enrolled the first...

read more

Candid Advice For Cash-Strapped Startups From A Biotech Venture Capitalist

By Josh Baxt, BioSpace.com Exclusive Story July 21, 2014 In a sense, Niall O’Donnell, Ph.D., and his colleagues at RiverVest Venture Partners run a biomedical adoption agency. They track down innovative discoveries, help raise them for a while and then find a good home, either at a pharmaceutical company or through public markets. For cash-strapped startups, this represents an opportunity, but they need to understand the rules. RiverVest is trying to build companies in five years or less, and that means having excellent IP and a...

read more

ZS Pharma Completes Patient Enrollment in ZS004, Its Second Phase 3 Study of ZS-9 in Patients with Hyperkalemia

Company expects to announce top-line results late Q3 or early Q4 2014 Coppell, Texas – July 14, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has completed enrollment in ZS004, its second Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate), a novel investigational treatment for hyperkalemia. This randomized, double-blind, placebo-controlled study is designed to confirm, over a longer treatment period, the positive...

read more

Otonomy Files Registration Statement for Proposed Initial Public Offering

SAN DIEGO, July 14, 2014 /PRNewswire/ – Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Otonomy. The number of...

read more

ZS Pharma Announces Allowance of Two U.S. Patent Applications for ZS-9

Applications cover composition of matter and methods of treating hyperkalemia and carry a patent term to at least 2032 Coppell, Texas – July 8, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Numbers 13/371,080 and 14/036,489 for ZS-9 (sodium zirconium cyclosilicate), the Company’s product candidate in Phase 3...

read more

ZS Pharma Announces Start of Enrollment of Phase 3 Long-Term Maintenance Study of ZS-9 in Patients with Hyperkalemia

–Open-Label Safety Study Evaluating Long-Term Safety and Efficacy of Oral Investigational Hyperkalemia Treatment— Coppell, Texas – June 26, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that it has begun enrolling patients in ZS005, a Phase 3 open-label, 12-month, long-term maintenance study of ZS-9, an investigational treatment for hyperkalemia. This Phase 3 trial is designed to further add to the clinical experience to date by...

read more
some there i have read what i are able to get facebook likes pick out